Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a proinflammatory participant in atherosclerosis and a potential biomarker for coronary heart disease. The effects of low-density lipoprotein (LDL) apheresis on Lp-PLA(2) levels were evaluated in 8 patients with cardiovascular disease. Each patient received 5 LDL apheresis treatments over a 3-month period. The mean direct LDL cholesterol level reduction was 60% (252 to 100 mg/dl). LDL apheresis acutely reduced Lp-PLA(2) by 21.4%. Over the course of treatment, Lp-PLA(2) levels were reduced by 29%. Chronic LDL apheresis significantly reduces Lp-PLA(2) independent of LDL cholesterol, which may be a potential mechanism by which LDL apheresis diminishes coronary heart disease risk.
Moriarty
Patrick M
PM
Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, Kansas 66160, USA. pmoriart@kumc.edu <pmoriart@kumc.edu>
Gibson
Cheryl A
CA
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000368:Aged; D001781:Blood Component Removal; D002318:Cardiovascular Diseases / Q000097:blood / Q000628:therapy*; D008078:Cholesterol, LDL / Q000097:blood*; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010741:Phospholipases A / Q000097:blood*; D054467:Phospholipases A2; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D010741:Phospholipases A; D054467:Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase